The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2021 | Novel targets in multiple myeloma
Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses current and emerging targets for multiple myeloma monoclonal antibodies (MAbs). Novel bispecific antibody treatments such as elranatamab, which binds to CD3 on T-cells and B-cell maturation antigen (BCMA), have favorable efficacy and safety profiles. Cytokine release syndrome is a side effect of these treatments, but is manageable with steroids and IL-6 antagonists such as tocilizumab. Bispecific antibodies with alternative targets highly expressed on multiple myeloma cells such as GPRC5D and FcRH5 have also shown promise. This interview took during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.
